Please use this identifier to cite or link to this item:
Title: Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes
Author: Zarranz Ventura, Javier
Romero Núñez, Bárbara
Bernal Morales, Carolina
Velázquez Villoria, Daniel
Sala Puigdollers, Anna
Figueras Roca, Marc
Copete, Sergio
Distefano, Laura
Boixadera, Anna
García Arumí, José
Adán Civera, Alfredo
Hospital Clínic-Hospital Vall de Hebron Intravitre
Keywords: Edema
Pròtesis internes
Stents (Surgery)
Issue Date: 11-Nov-2020
Publisher: BioMed Central
Abstract: Background: To identify different response patterns to intravitreal dexamethasone implants (IDI) in naïve and previously treated (PT) diabetic macular edema (DME) eyes in a real-life setting. Methods: 342 IDI injections (203 DME eyes) were included. Number of IDI injections, percentage (%) of eyes with 1, 2, 3 and ≥ 4 injections, time to reinjections, visual acuity (VA), intraocular pressure (IOP) and central retinal thickness (CRT) were evaluated for naïve and PT DME eyes over 24 months. Results: Mean number of injections was significantly lower in naïve vs PT DME eyes (1.40 ± 0.9 vs 1.82 ± 0.9, p < 0.001). The percentage of eyes receiving 1 injection was significantly higher in naïve vs PT DME eyes (76.1 vs 47.7), (p < 0.001). However, it was significantly lower for 2 (16.4 vs 29.4), or 3 injections (1.4 vs 17.6) (both p < 0.001), with no differences in eyes receiving ≥4 injections (5.9 vs 5.1 respectively, p = 0.80). Mean time to reinjection was not significantly different between both groups for the second, third and fourth injection (9.6 ± 4.0 vs 10.0 ± 5.5, p = 0.75, 13.2 ± 4.0 vs 16.0 ± 3.5, p = 0.21 and 21.7 ± 3.8 vs 19.7 ± 5.8, p = 0.55). VA scores were consistently better in naïve vs PT DME eyes at all studied timepoints, with no significant differences in CRT reduction or adverse effect rates. Conclusion: Naïve DME eyes received lower number of IDI injections and showed better VA levels than PT DME eyes for 24 months in a real-world setting. This data supports the IDI use in early DME stages and provide further evidence of better IDI response when used as first-line therapy.
Note: Reproducció del document publicat a:
It is part of: BMC Ophthalmology, 2020, vol. 20, num. 1, p. 443
Related resource:
ISSN: 1471-2415
Appears in Collections:Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
710224.pdf990.13 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons